Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ascendis Pharma A/S - Ordinary Share (NQ:ASND)

260.72 +1.44 (+0.56%)
Delayed Quote Updated: 10:35 AM EST, Nov 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ascendis Pharma A/S - Ordinary Share

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Ascendis (ASND) Q3 2026 Earnings Call Transcript ↗
Yorvipath sales doubled as Ascendis eyes a new therapy area 
Via The Motley Fool
Topics Earnings
Ascendis Pharma (NASDAQ:ASND) Offers Strong Growth With a Quality Technical Setup ↗
Via Chartmill
Ascendis Pharma (NASDAQ:ASND): Strong Growth Meets a High-Quality Technical Setup ↗
Via Chartmill
Ascendis Pharma (NASDAQ:ASND): A Fitting Candidate for Affordable Growth Investors ↗
Via Chartmill
Ascendis Pharma (NASDAQ:ASND) Passes Minervini Trend Template and High Growth Momentum Screen ↗
Via Chartmill
News headline image
If You Invested $1000 In Ascendis Pharma Stock 10 Years Ago, You Would Have This Much Today ↗
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 16.69% on an annualized basis producing an average annual return of 30.07%. Currently, Ascendis Pharma has a market... 
Via Benzinga
Ascendis Pharma (NASDAQ:ASND) Combines High Growth Momentum with a Breakout Setup ↗
Via Chartmill
Ascendis Pharma (ASND) Shows High Growth Momentum With Bull Flag Breakout Setup ↗
Via Chartmill
ASCENDIS PHARMA A/S (NASDAQ:ASND) Screens as a High-Growth Momentum Candidate ↗
Via Chartmill
Ascendis Pharma (NASDAQ:ASND) Shares Drop After Q4 Earnings Miss on Wider-Than-Expected Loss ↗
Via Chartmill
Topics Earnings
News headline image
Ascendis Pharma (ASND) Q2 2026 Earnings Call Transcript ↗
Revenue surged 105% year-over-year as three approved products scale globally. 
Via The Motley Fool
Topics Earnings
News headline image
Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration Patients
From Eyconis Inc.
Via GlobeNewswire
News headline image
Ascendis Pharma A/S Q2 Earnings Call Highlights ↗
Ascendis Pharma A/S (NASDAQ:ASND) reported second-quarter 2026 total revenue of EUR 339 million, including EUR 315 million in product revenue, as demand for its three commercial TransCon-based... 
Via MarketBeat
Topics Earnings
ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) Combines Minervini Trend Template with High Growth Momentum ↗
Via Chartmill
News headline image
Here's How Much $100 Invested In Ascendis Pharma 5 Years Ago Would Be Worth Today ↗
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 5 years by 5.62% on an annualized basis producing an average annual return of 17.21%. Currently, Ascendis Pharma has a market... 
Via Benzinga
News headline image
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma ↗
Ascendis Pharma develops long-acting therapies for rare endocrine and pediatric diseases using its proprietary TransCon technology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Energy Fund Yielding 7% and Up 14% in a Year Still Wasn’t Enough to Stop This $3 Million Exit ↗
The Kayne Anderson Energy Infrastructure Fund targets U.S. energy infrastructure, emphasizing income from MLPs and related equities. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Ascendis (ASND) Q1 2026 Earnings Call Transcript ↗
Ascendis (ASND) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Ascendis Pharma Completes Strategic Trifecta with U.S. Launch of YUVIWEL and Seven-Year Orphan Exclusivity
In a move that signals a transformative shift from a clinical-stage biotech to a commercial-market leader, Ascendis Pharma (NASDAQ: ASND) officially launched its third major product, YUVIWEL... 
Via MarketMinute
Topics Economy
News headline image
Agriculture Stock Up 53% Draws $12 Million Bet. Here's What Long-Term Investors Should Know ↗
This agribusiness firm delivers grain, renewables, and plant nutrient solutions to commercial and industrial clients worldwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Ascendis (ASND) Q4 2025 Earnings Call Transcript ↗
Ascendis (ASND) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million ↗
Praxis Precision Medicines targets neurological and psychiatric disorders with a pipeline of precision therapies for CNS conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position ↗
Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology. 
Via The Motley Fool
News headline image
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗
Apogee Therapeutics develops biologic therapies targeting dermatology and respiratory conditions, with lead candidates in clinical trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges ↗
Arcellx develops next-generation cell therapies targeting multiple myeloma and other hematologic cancers in the biotechnology sector. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Ascendis Pharma (ASND) Q4 2025 Earnings Transcript ↗
Ascendis Pharma (ASND) Q4 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Ascendis Pharma (NASDAQ:ASND) Passes Minervini's Trend Template and High Growth Momentum Scan ↗
Ascendis Pharma (ASND) meets Mark Minervini's strict criteria, showing a powerful technical uptrend paired with explosive revenue growth over 269%. 
Via Chartmill
News headline image
Why Dyne Therapeutics Stock Was Crushing it This Week ↗
The company has solid potential with its development of drugs targeting muscle disorders. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
European ADRs Navigate Choppy Waters: Pharma Sector Shows Resilience Amidst Broader Market Volatility
European American Depositary Receipts (ADRs) have recently experienced a period of significant fluctuation, reflecting a broader climate of market volatility that has ripple across global financial... 
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
News headline image
Ascendis (ASND) Q3 2025 Earnings Call Transcript ↗
Ascendis (ASND) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.